RxDoctor Payments Data

Amanjit Dhatt, MD

Internal Medicine · Reno, NVNPI 1811973795

Payments from drug & device makers

$3,790in general payments, 2019–2025

Across 220 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$636
  • GSK$607
  • Regeneron Healthcare Solutions, Inc.$537
  • Sanofi$272
  • Pharming Healthcare, Inc.$228
  • Boehringer Ingelheim$172
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$391%
  • Food & beverage$3,54393%
  • Education$2085%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,790 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$148,877
Medicare patients
234
Services billed
11,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5023$97,645
ArexvyRsvpref3 Antigen/As01e/Pf277$81,371
ShingrixVaricella-Zoster Ge/As01b/Pf279$56,075
XolairOmalizumab15$43,996
Dupixent SyringeDupilumab11$39,961
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$36,843
Spiriva RespimatTiotropium Bromide15$13,469
Arnuity ElliptaFluticasone Furoate34$12,358
Epinephrine58$9,689
Breo ElliptaFluticasone/Vilanterol12$7,752
Boostrix TdapDiphth,pertuss(Acell),tet Vac100$5,738
Montelukast Sodium284$4,865
Cromolyn Sodium24$3,960
Azelastine Hcl75$3,363
Ipratropium Bromide70$3,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Shingrix, Trelegy Ellipta, Arnuity Ellipta, Breo Ellipta$607$194,399646 claims
CSL BehringHizentra$170$97,64523 claims
Boehringer IngelheimSpiriva Respimat$172$13,46915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →